Crinecerfont
Small molecule
Evidence outlook
Approved: Congenital Adrenal Hyperplasia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03525886 NCT03525886 · Congenital Adrenal Hyperplasia This was a small, nonrandomized, open-label sequential-cohort study without a comparator; 18 unique participants received one of four crinecerfont regimens, with some participating in more than one cohort. Its primary outcome was a biomarker change rather than a direct clinical outcome, and there was no formal between-group efficacy comparison. Registry: NCT03525886 | 2 | Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages (Baseline and Day 14) 2020-04-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 3 more trials
NCT04045145 NCT04045145 · Congenital Adrenal Hyperplasia The study was a small, open-label, single-arm trial of 8 participants with no comparator or blinding. Its primary endpoint was a biomarker change rather than a clinical outcome, and although 17-OHP decreased, there was no controlled comparison to determine whether crinecerfont caused the change. Registry: NCT04045145 | 2 | Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average) (Baseline, Day 14) 2021-07-02 | Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average) (Baseline, Day 14): Crinecerfont 50 mg -69.48 percent change (IQR -89.2 to -23.05) | Weak signal | link ↗ |
NCT04806451 NCT04806451 · Congenital Adrenal Hyperplasia Patients were randomized 2:1 (69 vs 34) to crinecerfont or placebo with participants, care providers and investigators masked, and the primary comparison was significant (least-squares mean difference -267.8 ng/dL, p=0.0002). The primary endpoint is a blood hormone level rather than a clinical outcome, and the sample is modest, which keeps the grade at moderate. Registry: NCT04806451 | 3 | Change From Baseline in Serum Androstenedione at Week 4 (Baseline, Week 4) 2023-03-10 | Change From Baseline in Serum Androstenedione at Week 4 (Baseline, Week 4): Placebo 70.986 ng/dL (Standard Error 56.198) | Crinecerfont -196.789 ng/dL (Standard Error 39.369) | Partial signal | link ↗ |
CAHtalyst NCT04490915 · Congenital Adrenal Hyperplasia Patients were randomized 2:1 (122 vs 60) to crinecerfont or placebo with participants, care providers and investigators masked. The primary endpoint, the reduction in daily glucocorticoid dose, was significantly better with crinecerfont (least-squares mean difference -17.0 percentage points, p<0.0001). Registry: NCT04490915 | 3 | Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24 (Baseline, Week 24) 2023-07-19 | Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24 (Baseline, Week 24): Placebo -10.3 percent change (Standard Error 3.247) | Crinecerfont -27.322 percent change (Standard Error 2.418) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Crinecerfont to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
2029 (1)
September 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent